Biotechnology
Ultimovacs Cancer Vaccine Faces Significant Challenges After Third Consecutive Failure
Ultimovacs, cancer vaccine, phase 2 trial, clinical failure, financial struggles, biotechnology
Biogen Retains Biosimilars as Eisai-Partnered Leqembi Advances Amid Business Shift
Biogen, biosimilars, Leqembi, Eisai, Alzheimer’s disease, business pivot, pharmaceuticals, biotechnology
WuXi AppTec Faces Revenue Decline Amid Looming BIOSECURE Act Threat
WuXi AppTec, BIOSECURE Act, Revenue Decline, Biotechnology, US-China Relations
Can Element Biosciences Challenge Illumina in the DNA Sequencing Market?
Element Biosciences, Illumina, DNA sequencing, next-generation sequencing (NGS), Avidity Base Chemistry (ABC), sequencing by synthesis (SBS), Cloudbreak, Aviti sequencer, genomics, biotechnology, market competition
Lilly Secures Option to Acquire Radionetics for $1 Billion in Radiopharma Deal
Eli Lilly, Radionetics Oncology, Radiopharmaceuticals, G Protein-Coupled Receptors, Solid Tumors, Biotechnology, Acquisition
Alumis Secures $250 Million in Downsized Initial Public Offering
Alumis, Immunology Biotech, IPO, Initial Public Offering, Funding, Biotechnology
Syncona Expands Portfolio with Investments in iOnctura and Yellowstone, Two Cancer-Focused Biotechs
Syncona, iOnctura, Yellowstone, cancer biotechs, portfolio expansion, investment, biotechnology
Decheng Capital Seeks $700 Million for Fifth Life Sciences Fund Amidst VC Surge
Decheng Capital, Life Sciences Fund, Venture Capital, Biotechnology, Investment Firm
ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition
ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing